"Targeted Fat Reduction Achieved"…GC Wellbeing's Injectable Succeeds in China Phase 3 Trial

Top-Line Results Achieved for RZL-012
Over 30% Difference in Response Rate in Primary Endpoint
Emerging as a New Body Contouring Option

Raziel Therapeutics (Raziel), a biotechnology company and partner of GC Wellbeing, announced on September 3 that its next-generation fat-dissolving injectable, RZL-012, has achieved key efficacy and safety endpoints in a Phase 3 clinical trial in China.

This Phase 3 trial was a large-scale pivotal registration clinical trial conducted by Zubestar, an affiliate of Shanghai Fosun Pharmaceutical, Raziel’s Chinese partner, involving 480 adult patients with submental fat (double chin).

The trial results showed that RZL-012 met both primary and secondary efficacy endpoints at day 84 after just one treatment cycle. In particular, the primary efficacy evaluation demonstrated a statistically significant difference in response rate of more than 30 percentage points compared to the placebo group, confirming significant fat reduction effects and safety.

Fosun Pharma and Raziel plan to submit a New Drug Application (NDA) to China’s National Medical Products Administration (NMPA) based on these results. In addition to the double chin indication, further clinical trials are planned to expand indications to body contouring areas such as the abdomen and thighs.

RZL-012 is a next-generation investigational drug candidate for local lipolysis that induces irreversible apoptosis of targeted fat cells. It is being developed to reduce localized fat deposits with only one to two injections per treatment cycle, which requires fewer administrations compared to existing fat-dissolving procedures, and is gaining attention as a new non-surgical body contouring option.

Recently, as the GLP-1 class obesity treatment market has been growing rapidly, demand has also increased among patients seeking to manage specific body areas after weight loss. GC Wellbeing aims to position RZL-012 as a body contouring solution that can be used before, after, or in combination with GLP-1–based weight loss therapies.

GC Wellbeing holds the exclusive domestic license for RZL-012 in Korea.

A GC Wellbeing representative said, “China is one of the key regions in the global medical aesthetics market, and this Phase 3 trial result confirmed the commercialization potential of RZL-012. With rising demand for body contouring therapies, we will continue to build a differentiated portfolio that bridges obesity and medical aesthetics.”

This content was produced with the assistance of AI translation services.